William R. Schelman, Ph.D. - Publications

2000 University of Illinois, Urbana-Champaign, Urbana-Champaign, IL 
Cell Biology, Molecular Biology

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, et al. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1475-81. PMID 25512461 DOI: 10.1200/JCO.2014.55.7504  0.68
2015 LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G. A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational New Drugs. 33: 169-76. PMID 25318436 DOI: 10.1007/S10637-014-0166-6  0.68
2014 Bultman EM, Brodsky EK, Horng DE, Irarrazaval P, Schelman WR, Block WF, Reeder SB. Quantitative hepatic perfusion modeling using DCE-MRI with sequential breathholds. Journal of Magnetic Resonance Imaging : Jmri. 39: 853-65. PMID 24395144 DOI: 10.1002/Jmri.24238  0.68
2014 Paul Olson TJ, Hadac JN, Sievers CK, Leystra AA, Deming DA, Zahm CD, Albrecht DM, Nomura A, Nettekoven LA, Plesh LK, Clipson L, Sullivan R, Newton MA, Schelman WR, Halberg RB. Dynamic tumor growth patterns in a novel murine model of colorectal cancer. Cancer Prevention Research (Philadelphia, Pa.). 7: 105-13. PMID 24196829 DOI: 10.1158/1940-6207.Capr-13-0163  0.68
2014 Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Investigational New Drugs. 32: 323-9. PMID 24114123 DOI: 10.1007/S10637-013-0035-8  0.68
2014 Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Investigational New Drugs. 32: 295-302. PMID 23860642 DOI: 10.1007/S10637-013-9999-7  0.68
2014 Brodsky EK, Bultman EM, Johnson KM, Horng DE, Schelman WR, Block WF, Reeder SB. High-spatial and high-temporal resolution dynamic contrast-enhanced perfusion imaging of the liver with time-resolved three-dimensional radial MRI. Magnetic Resonance in Medicine. 71: 934-41. PMID 23519837 DOI: 10.1002/Mrm.24727  0.68
2013 Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, et al. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Investigational New Drugs. 31: 1539-46. PMID 24114121 DOI: 10.1007/S10637-013-0029-6  0.68
2013 Kolesar JM, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR. Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer Chemotherapy and Pharmacology. 72: 661-7. PMID 23903894 DOI: 10.1007/S00280-013-2242-6  0.68
2013 Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology. 14: 882-92. PMID 23810788 DOI: 10.1016/S1470-2045(13)70240-7  0.68
2013 LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Investigational New Drugs. 31: 943-8. PMID 23263993 DOI: 10.1007/s10637-012-9916-5  0.68
2013 Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S. Hereditary and sporadic cancers respond to niraparib Cancer Discovery. 3. DOI: 10.1158/2159-8290.Cd-Rw2013-148  0.68
2012 Chung V, Heath EI, Schelman WR, Johnson BM, Kirby LC, Lynch KM, Botbyl JD, Lampkin TA, Holen KD. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemotherapy and Pharmacology. 69: 733-41. PMID 22020315 DOI: 10.1007/s00280-011-1756-z  0.68
2011 Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, Eickhoff J, Chen H, Loconte NK. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. The Oncologist. 16: 835-43. PMID 21632454 DOI: 10.1634/Theoncologist.2011-0031  0.68
2011 Lubner SJ, Kunnimalaiyaan M, Holen KD, Ning L, Ndiaye M, Loconte NK, Mulkerin DL, Schelman WR, Chen H. A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. The Oncologist. 16: 452-7. PMID 21393344 DOI: 10.1634/theoncologist.2010-0323  0.68
2011 Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. Experimental and Therapeutic Medicine. 2: 119-123. PMID 21373381 DOI: 10.3892/Etm.2010.165  0.68
2011 Schelman WR, Liu G, Wilding G, Morris T, Phung D, Dreicer R. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Investigational New Drugs. 29: 118-25. PMID 19763400 DOI: 10.1007/S10637-009-9318-5  0.68
2010 Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 66: 973-80. PMID 20127092 DOI: 10.1007/S00280-010-1250-Z  0.68
2009 Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 63: 1147-56. PMID 19082825 DOI: 10.1007/S00280-008-0890-8  0.68
2009 Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, et al. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 64: 45-51. PMID 18841362 DOI: 10.1007/S00280-008-0844-1  0.68
2008 Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. Journal of Inorganic Biochemistry. 102: 693-8. PMID 18061679 DOI: 10.1016/J.Jinorgbio.2007.10.013  0.68
2004 Schelman WR, Andres RD, Sipe KJ, Kang E, Weyhenmeyer JA. Glutamate mediates cell death and increases the Bax to Bcl-2 ratio in a differentiated neuronal cell line. Brain Research. Molecular Brain Research. 128: 160-9. PMID 15363891 DOI: 10.1016/J.Molbrainres.2004.06.011  0.68
2004 Schelman WR, Andres R, Ferguson P, Orr B, Kang E, Weyhenmeyer JA. Angiotensin II attenuates NMDA receptor-mediated neuronal cell death and prevents the associated reduction in Bcl-2 expression Molecular Brain Research. 128: 20-29. PMID 15337314 DOI: 10.1016/J.Molbrainres.2004.06.001  0.68
1997 Schelman WR, Kurth JL, Berdeaux RL, Norby SW, Weyhenmeyer JA. Angiotensin II type-2 (AT2) receptor-mediated inhibition of NMDA receptor signalling in neuronal cells. Brain Research. Molecular Brain Research. 48: 197-205. PMID 9332716 DOI: 10.1016/S0169-328X(97)00093-4  0.68
Show low-probability matches.